One of our special focuses in the latest issue of the Wall Street Transcript is on Specialty Pharmaceuticals. We asked several analysts to talk to us about what the economic downturn is going to mean for this space. Louise Chen of Collins Stewart, LLC had this to say:
Ms. Chen: I think what you’re seeing in health care in general is that health care is no longer a defensive space. A lot of healthcare companies in the space that I cover, the spec pharma companies, get a portion of their income from discretionary spending. Allergan (AGN) and Medicis (MRX) have medical aesthetic products, and as a result of the economic downturn, consumers are pulling back on spending for these things. Advanced Medical Optics (EYE), which is being acquired by Abbott (ABT), that company did lasik surgery and that’s thousands of dollars out of pocket. So you’ll see that stock also getting hurt by the economic downturn. That’s a trend that we’re seeing going forward in the spec pharma space.
For the complete Specialty Pharmaceuticals report, including a complete interview with Ms. Chen as well as interviews with analysts covering a variety of aspects of this space, click here.
Longer-Term Opportunities in Canadian Life Insurance
July 27, 2011
Longer-Term Horizon Required for Defense Investing
November 23, 2011
Solar Capital Ltd. (SLRC) Strengthens Balance Sheet by Accessing Longer-Term Capital
April 05, 2013
30 Year Treasury Investment No Longer an Alternative for Portfolios: What Now?
April 10, 2019
Aerospace & Defense on the Defensive
November 24, 2008
